Navigation Links
NanoSmart™ Pharmaceuticals, Inc., Opens New Headquarters - Begins Development of New Drug Delivery Platform for Cancer
Date:9/7/2011

LAGUNA HILLS, Calif., Sept. 7, 2011 /PRNewswire/ -- NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA.  The facility provides the administrative and laboratory work space necessary to begin formal development of its initial product pipeline.

"Our new location gives us a physical presence in Orange County, California and allows us to move forward with our strategic development goals," said Dr. Henry Smith, CEO of the company.  "We are excited about the opportunity to develop our initial products and conduct formal, nonclinical studies leading towards our initial regulatory filings," said Dr. Smith.

About the technology:

NanoSmart™ is developing a patented, novel anti-tumor targeting platform based on fully-human autoimmune antibodies.  These antibodies target areas of necrosis found in many different types of cancer.  NanoSmart's drug delivery system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy.  By combining these antibodies with different cancer drugs, NanoSmart has the potential to develop a very large number of novel biopharmaceutical products.

NanoSmart™ Pharmaceuticals, Inc., is a privately-held company engaged in developing novel methods to treat cancer and other diseases.  The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer.  This press release may contain forward-looking statements regarding future events.  There can be no assurance that such development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

For more information contact us at (949) 305-2020
E-mail us at info@nanosmartpharmaceuticals.com
Investor Relations: (310) 951-3282

Please visit our website:  www.nanosmartpharmaceuticals.com


'/>"/>
SOURCE NanoSmart Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
2. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
3. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
4. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
5. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
6. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
7. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
8. Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
9. K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
10. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Dr. Carol Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is hypnosis ... with habit control (substances, smoking, weight control), pain relief (chronic and acute), birthing ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
Breaking Medicine News(10 mins):